Five hyperCORE International alliance partners have been recognized by Pfizer as Top 20 Enrollers for their landmark COVID-19 vaccine study. Aventiv Research, Benchmark Research, Clinical Trials of Texas, IACT Health, and Quality Clinical Research have received this prestigious distinction, helping to solidify their statuses as leading clinical research companies and furthering hyperCORE International’s mission of being the premier super network of clinical trial sites across the globe.
Pfizer’s clinical trial began in March 2020, as the pandemic forced the world into a standstill. Positive data from Pfizer’s Phase I/II trials was originally published in August 2020. Phase III data, published 3 months later in November, showed an incredibly high efficacy rate of 95>% which led to the vaccine’s subsequent Emergency Use Approval from the FDA in December 2020.
Of the 154 sites participating globally in Pfizer’s COVID-19 vaccine study, Aventiv Research, Benchmark Research, Clinical Trials of Texas, IACT Health, and Quality Clinical Research contributed more than 2,000 of the 43,000+ total patient volunteers. Collectively, hyperCORE International’s sites have contributed approximately 10% of patients for all COVID-19 vaccine studies worldwide.
Many hyperCORE International alliance partners, including these top enrollers, are continuing COVID-19 research as vaccine developers further monitor safety and explore efficacy, especially in the face of new, emerging variants.
Together, our sites rose to the challenge of putting an end to the pandemic. And even though our work is far from over, we are incredibly proud to be involved in such a historic moment for public health around the world.